Seven clinical update sessions were held throughout the conference, giving delegates an insight into the latest findings on the management of various cancers and the toxicities associated with anticancer therapy.
Dr Graham Dark (Senior Lecturer in Medical Oncology & Cancer Education, Newcastle University) presented an update on ovarian cancer, including its pathogenesis and treatment. He discussed highlights from various promising avenues of clinical research, including use of vascular endothelial growth factor inhibitors such as bevacizumab in combination with chemotherapy, the role of biomarkers such as CA-125, the potential of p53 mutation status as a prognostic indicator, and the use of poly-ADP-ribose polymerase inhibitors.
Ovarian Cancer Video Presentation Slides
Margaret Gibbs (Specialist Senior Pharmacist, St Christopher’s Hospice) presented a session on the management of neuropathic pain, a difficult-to-treat symptom affecting up to 40% of patients with cancer. There are various causes, including tumour growth, metastases in the brain or spinal cord and iatrogenises. The treatments available for neuropathic pain include antidepressants, antiepileptics, opioids, topical anaesthetics and N-methyl-D-aspartate receptor antagonists.
Management of Neuropathic Pain Video Presentation Slides
Dr Pam McKay (Consultant Haematologist, Beatson West of Scotland Cancer Centre, Glasgow) gave a presentation on the classification and treatment of rare lymphomas. As a group, non-Hodgkin lymphomas are the sixth most common cancer in the UK, although there are a large number of distinct lymphoma types with differing aetiology, characteristics and treatments. Treatment options depend on the likely clinical course of each lymphoma, and its suitability for specific therapies, such as rituximab.
Rarer Lymphomas Video Presentation Slides
Jennifer Laskey (Senior Clinical Effectiveness Pharmacist, Beatson West of Scotland Cancer Centre, Glasgow) talked about the toxicity of tyrosine kinase inhibitors (TKIs), discussing their mechanism of action and indications. Jennifer noted that the potency and specificity of each drug influences its side effects, which commonly include fatigue, cardiac effects, gastrointestinal toxicities and skin toxicities. TKI-associated toxicities should be proactively managed, by identifying those patients most at risk, providing symptomatic management where appropriate, and modifying doses when necessary to minimise the negative effects of treatment on patient quality of life.
Toxicity of Tyrosine Kinase Inhibitors Video Presentation Slides
Dr Robert Jones (Senior Lecturer & Honorary Consultant in Medical Oncology, University of Glasgow) presented an overview of the treatment of metastatic, castration-resistant prostate cancer. Approximately 30–40% of cases progress to metastatic disease, which is the sole cause of death from prostate cancer. Treatment options are limited, with the mainstay being docetaxel, which can be followed by abiraterone and cabazitaxel. Recent evidence suggests that enzalutamide is not only an effective substitute for abiraterone, but may also improve quality of life in this patient population.
Castrate-Resistant Prostate Cancer Video Presentation Slides
Dr Sally Clive (Consultant Medical Oncologist, Edinburgh Cancer Centre) considered the management of colorectal cancer (CRC). Treatment of CRC can have a number of aims, ranging from curative therapy for early-stage disease, to palliative treatment for metastatic disease, with the primary goal of maximising the duration of good quality of life. Treatments include targeted therapies such as bevacizumab and cetuximab, as well as oxaliplatin-based chemotherapy.
Colorectal Cancer Video Presentation Slides
The final clinical update session was presented by Dr Jeff White (Consultant Medical Oncologist, Beatson West of Scotland Cancer Centre, Glasgow), and focused on gastrointestinal stromal tumours (GIST). This rare sarcoma is relatively well understood, with two main causative mutations identified. Medical management of GIST is based on treatment with TKIs, with imatinib used as first-line therapy and sunitinib in the second line. Several drugs have been shown to be effective as third-line treatment, including the recently approved kinase inhibitor regorafenib.
Gastrointestinal Stromal Tumours Video Presentation Slides